在获得的血栓性血栓细胞衰竭紫外线中管理手术复发风险:系统性审查
Morgana Pinheiro Maux Lessa1, Alexandre Soares Ferreira Junior1,2, Margaret Graton3
1Department of Medicine, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil.
Research and practice in thrombosis and haemostasis
|August 8, 2024
概括
血栓性血栓塞性紫色素 (TTP) 复发可能发生在手术后. 术前预防和ADAMTS-13活动监测可以降低手术后TTP复发的风险.
科学领域:
- 血液学 血液学 血液学
- 手术并发症 手术并发症
- 血栓式微血管病变 (Thrombotic Microangiopathies) 是一种导致血栓形成的小血管病变.
背景情况:
- 血栓性血栓塞性紫色素 (TTP) 是一种罕见的,危及生命的血液学疾病.
- 外科手术是TTP复发的潜在触发因素.
- 进行手术的TTP患者的管理需要仔细考虑预防策略.
研究的目的:
- 系统地审查有关血栓性血栓细胞性紫外线 (TTP) 术前预防的文献.
- 评估旨在减少TTP患者手术复发风险的干预措施的有效性.
- 评估ADAMTS-13活动监测对预测和预防术后TTP复发的有用性.
主要方法:
- 发表的研究的系统审查.
- 对手术前TTP预防策略的数据分析.
- 评估ADAMTS-13活动水平与手术复发之间的相关性.
- 对预防性治疗对术后TTP复发的影响的评估.
主要成果:
- 评估了手术前的血栓性血栓塞性紫外线 (TTP) 预防策略.
- 有证据表明,在手术前预先测量ADAMTS-13活性可能会提高风险评估.
- 手术前的TTP预防证明了降低手术复发可能性的潜力.
结论:
- 手术干预可以加速血栓性血栓细胞性紫外线 (TTP) 复发.
- 手术前的TTP预防和ADAMTS-13活动的监测是减轻手术复发风险的潜在策略.
- 需要进行进一步的研究,以确定术后TTP管理的最终指导方针.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
502
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
164
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164